Skip to content
Screener

DBV Technologies DBVT Stock-Based Comp

Stock-Based Comp at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$5.31M+95.2%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$8.45M-14.6%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$2.32M+46.1%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$8.41M-8.5%
Alumis Inc. logo
Alumis Inc.ALMS
$12.34M+76.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$3.36M-13.9%

Segments

By product

See full
Expenses by nature$1.2M

Other financials

Income statement

See full
Revenue$700.0K-53.3%
Operating income-$50.6M-23.1%
Net income-$50.4M-20.3%
EPS (diluted)-$0.12+61.3%

Balance sheet

See full
Cash & equivalents$174.9M+69.5%
Total debt$7.7M+0.1%
Total equity$160.4M+86.1%
Total assets$223.2M+55.6%

Cash flow

See full
Operating cash flow-$52.6M-55.2%
CapEx$400.0K
Free cash flow-$53.0M-56.3%

Valuation

See full
Market cap$847.16M+218%
Enterprise value$679.96M+297%
P/S168.8×+100×

Profitability

See full
Operating margin-3,543.1%+523pp
Net margin-3,506.5%+442pp
FCF margin-3,399.3%+3,268pp

Returns & leverage

See full
Return on equity-142.7%-5.0pp
Debt / equity0.0×
Current ratio3.7×+1.3×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: DBV Technologies’s 10-Q, filed July 16, 2026.

Filed
Jul 16, 2026, 4:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-048453
Line itemNotesSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Net loss for the period$$(98.0)(69.0)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization and accrued contingencies4/111.51.7
Expenses related to share-based payments106.02.9
Inventory write-downs5.610.3
Other0.11.0
Changes in operating assets and liabilities:
Decrease (increase) in inventories and work in progress(5.6)(10.3)

Item 1C. Condensed Consolidated Statements of Financial Position (Unaudited) as of

FAQ

What is DBV Technologies's stock-based comp?
DBV Technologies (DBVT) reported stock-based comp of $3.7M in Q2 2026.
How has DBV Technologies's stock-based comp changed year-over-year?
DBV Technologies's stock-based comp increased by 208.3% year-over-year, from $1.2M to $3.7M.
What is the long-term trend for DBV Technologies's stock-based comp?
Over 3 years (2022 to 2025), DBV Technologies's stock-based comp has grown at a 2.3% compound annual growth rate (CAGR), from $5.03M to $5.39M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about DBV Technologies's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude